myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Parallel-group, prospective, randomized, controlled phase III trial of home High flow Nasal Therapy (HFNT) via myAirvo 3 plus usual COPD medical care vs. usual COPD medical care, for at least 1 year and up to two years in 642 GOLD Grade D, Stages II-IV patients with moderate to very severe COPD at risk for moderate and severe exacerbations with a prior history of severe exacerbation requiring hospitalization within the past 6 weeks.

NCT Number	NCT05204888
Lead Sponsor	Temple University Collaborators: Fisher and Paykel Healthcare
Conditions	COPD
Enrollment	642 participants
Start Date	2022-02-02
Primary Completion	2027-01 (estimated)
Study Completion	2027-03 (estimated)
Updated on ClinicalTrials.gov	2025-02-06